Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study in People With Pulmonary Fibrosis to Monitor Cough With a Wearable Device
NCT05670587 · View on ClinicalTrials.gov ↗
Study Summary
This study is open to adults aged 18 years and older who have pulmonary fibrosis with or without a known cause (or other forms of pulmonary fibrosis). The purpose of this study is to better understand coughing in people with pulmonary fibrosis. To do this, a wearable cough monitor called Strados Remote Electronic Stethoscope Platform (RESP) is used. This device will measure how often and how forceful coughing is in people with pulmonary fibrosis. All participants in the study get the device. It is placed on their skin over the chest. Participants are in the study for 3 months. During this time, they visit the study site 2 to 3 times. 4 visits are done at the participant's home by video call with the site staff. During the study, the device measures coughing over 24 hours. This is done on 4 days. Participants fill in questionnaires about their coughing and doctors regularly check participant's lung function. A breathing test that measures how well the lungs are working is performed both in the office and during home visits. The doctors also regularly check participants' health and take note of any unwanted effects. This study will also record patients' experiences using the cough monitor and video assisted breathing tests at visits 3, 4, 5 and 6 at home.
Conditions Studied
Interventions
- DEVICE A wearable cough monitoring device, the Strados Labs RESPᵀᴹ sensor, with an accompanying mobile application (App) for data collection
Study Locations (13)
Other
- Aalst - HOSP Onze-Lieve-Vrouw — Aalst
- Jessa Ziekenhuis - Campus Virga Jesse — Hasselt
- Kortrijk - HOSP AZ Groeninge Kennedylaan — Kortrijk
- Roeselare - HOSP AZ Delta — Roeselare
- Universitätsklinikum Freiburg — Freiburg im Breisgau
- Universitätsklinikum Jena — Jena
- Rijnstate Hospital — Arnhem
- Amphia Ziekenhuis — Breda
- Erasmus Medisch Centrum — Rotterdam
Colorado
- Critical Care, Pulmonary and Sleep Associates — Lakewood
Nevada
- Renown Regional Medical Center — Reno
North Carolina
- Southeastern Research Center — Winston-Salem
South Carolina
- Lowcountry Lung and Critical Care — Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2023-01-16 |
| Est. Completion | 2024-03-07 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05670587
The ClinicalTrials.gov registry entry for NCT05670587 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 203 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Pulmonary Fibrosis appearing as the primary indexed condition, and to 1 intervention — of which A wearable cough monitoring device, the Strados Labs RESPᵀᴹ sensor, with an accompanying mobile application (App) for data collection is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05670587 reports 13 study locations spanning 5 distinct geographic areas — top geographies include Other, Colorado, Nevada. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05670587 about?
NCT05670587 is a clinical study titled "A Study in People With Pulmonary Fibrosis to Monitor Cough With a Wearable Device". This study is open to adults aged 18 years and older who have pulmonary fibrosis with or without a known cause (or other forms of pulmonary fibrosis). The purpose of this study is to better understand coughing in people with pulmonary fibrosis. To do this, a wearable cough monitor called Strados Re...
What is the current status of trial NCT05670587?
This trial is currently completed. It is a NA study. The enrollment target is 53 participants. The study started on 2023-01-16. Estimated completion is 2024-03-07.
What conditions does trial NCT05670587 study?
This clinical trial studies the following conditions: Pulmonary Fibrosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05670587?
The interventions under investigation include: A wearable cough monitoring device, the Strados Labs RESPᵀᴹ sensor, with an accompanying mobile application (App) for data collection (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05670587?
This trial is sponsored by Boehringer Ingelheim, which has 203 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05670587 being conducted?
This trial has 13 study locations across Colorado, Nevada, North Carolina, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.